[go: up one dir, main page]

MA23212A1 - Procede - Google Patents

Procede

Info

Publication number
MA23212A1
MA23212A1 MA23523A MA23523A MA23212A1 MA 23212 A1 MA23212 A1 MA 23212A1 MA 23523 A MA23523 A MA 23523A MA 23523 A MA23523 A MA 23523A MA 23212 A1 MA23212 A1 MA 23212A1
Authority
MA
Morocco
Application number
MA23523A
Other languages
English (en)
Inventor
R Palepu Naseswara
M Venkatech Gopadi
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939311188A external-priority patent/GB9311188D0/en
Priority claimed from GB939316252A external-priority patent/GB9316252D0/en
Priority claimed from GB939318920A external-priority patent/GB9318920D0/en
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of MA23212A1 publication Critical patent/MA23212A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA23523A 1993-05-29 1994-05-27 Procede MA23212A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB939311188A GB9311188D0 (en) 1993-05-29 1993-05-29 Process
GB939316252A GB9316252D0 (en) 1993-08-05 1993-08-05 Process
GB939318920A GB9318920D0 (en) 1993-09-11 1993-09-11 Process

Publications (1)

Publication Number Publication Date
MA23212A1 true MA23212A1 (fr) 1994-12-31

Family

ID=27266706

Family Applications (1)

Application Number Title Priority Date Filing Date
MA23523A MA23212A1 (fr) 1993-05-29 1994-05-27 Procede

Country Status (13)

Country Link
EP (1) EP0701436B1 (fr)
JP (1) JPH08510752A (fr)
CN (1) CN1124452A (fr)
AP (1) AP9400645A0 (fr)
AT (1) ATE230981T1 (fr)
AU (1) AU684522B2 (fr)
CA (1) CA2164003A1 (fr)
DE (1) DE69432015T2 (fr)
ES (1) ES2189803T3 (fr)
IL (1) IL109770A0 (fr)
MA (1) MA23212A1 (fr)
NZ (1) NZ268172A (fr)
WO (1) WO1994027557A2 (fr)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9402203D0 (en) * 1994-02-04 1994-03-30 Smithkline Beecham Plc Pharmaceutical formulation
GB9407386D0 (en) 1994-04-14 1994-06-08 Smithkline Beecham Plc Pharmaceutical formulation
GB9416600D0 (en) * 1994-08-17 1994-10-12 Smithkline Beecham Plc Pharmaceutical formulation
PT862431E (pt) * 1995-09-07 2002-04-29 Smithkline Beecham Plc Utilizacao de uma formulacao farmaceutica pediatrica que compreende amoxicilina e clavulanato
TWI225402B (en) 1996-03-13 2004-12-21 Biochemie Gmbh Auxiliary-free agglomerates
AT407701B (de) * 1996-08-12 2001-05-25 Biochemie Gmbh Zur direkttablettierung geeignete mischung, die als wesentliche komponenten amoxicillin-trihydrat und das kaliumsalz der clavulansäure enthält und verfahren zur herstellung dieser mischung
FR2753904B1 (fr) 1996-10-01 1998-10-30 Gattefosse Ets Sa Composition pharmaceutique a liberation modifiee de principe actif, comportant une matrice, et procede de fabrication
IL119627A (en) 1996-11-17 2002-03-10 Yissum Res Dev Co PHARMACEUTICAL PREPARATIONS FOR THE CONTROLLED-RELEASE OF AN ACTIVE AGENT COMPRISING AT LEAST ONE β-LACTAM ANTIBIOTIC AGENT
DE19705538C1 (de) * 1997-02-14 1998-08-27 Goedecke Ag Verfahren zur Trennung von Wirkstoffen in festen pharmazeutischen Zubereitungen
SK110299A3 (en) * 1997-02-14 2000-08-14 Smithkline Beecham Lab Pharmaceutical formulations comprising amoxocyllin and clavulanate, preparation method and use thereof
US6692767B2 (en) 1997-09-19 2004-02-17 Shire Laboratories Inc. Solid solution beadlet
CA2305535A1 (fr) * 1997-10-03 1999-04-15 Gopadi M. Venkatesh Formes galeniques solides a liberation controlee au carbonate de lithium
PL334517A1 (en) * 1997-11-17 2000-02-28 Gist Brocades Bv Clavulate and one or more of exicipients containing granules
EP1685839B8 (fr) * 1997-12-22 2013-06-26 Euro-Celtique S.A. Formulation pharmaceutique pour administration orale comprenant en combinaison un agoniste et un antagoniste des récepteurs opiacés
EP1063973B1 (fr) 1998-03-19 2016-11-16 Bristol-Myers Squibb Company Systeme d'apport a liberation lente biphasique destine a des medicaments a solubilite elevee et procede associe
DE60003255T2 (de) * 1999-04-13 2004-05-06 Beecham Pharmaceuticals (Pte) Ltd. Neue Behandlungsmethode unter Verwendung einer hochdosierten Form von Amoxycillin und Kaliumclavulanat
US7250176B1 (en) 1999-04-13 2007-07-31 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection
US6294199B1 (en) 1999-04-13 2001-09-25 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising administering amoxycillin
US6878386B1 (en) 1999-04-13 2005-04-12 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6610328B2 (en) 2000-02-24 2003-08-26 Advancis Pharmaceutical Corp. Amoxicillin-clarithromycin antibiotic composition
US6565882B2 (en) 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
CA2399856C (fr) * 2000-02-24 2009-01-27 Edward M. Rudnic Composition antibiotique dotee d'inhibiteurs
US6632453B2 (en) 2000-02-24 2003-10-14 Advancis Pharmaceutical Corp. Ciprofoxacin-metronidazole antibiotic composition
US6627222B2 (en) 2000-02-24 2003-09-30 Advancis Pharmaceutical Corp. Amoxicillin-dicloxacillin antibiotic composition
US6991807B2 (en) 2000-02-24 2006-01-31 Advancis Pharmaceutical, Corp. Antibiotic composition
US6663890B2 (en) 2000-02-24 2003-12-16 Advancis Pharmaceutical Corp. Metronidazole antibiotic product, use and formulation thereof
US6730320B2 (en) 2000-02-24 2004-05-04 Advancis Pharmaceutical Corp. Tetracycline antibiotic product, use and formulation thereof
US6669948B2 (en) 2000-02-24 2003-12-30 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6623758B2 (en) 2000-02-24 2003-09-23 Advancis Pharmaceutical Corp. Cephalosporin-metronidazole antibiotic composition
US6667042B2 (en) 2000-02-24 2003-12-23 Advancis Pharmaceutical Corp. Fluroquinilone antibiotic product, use and formulation thereof
US7025989B2 (en) 2000-02-24 2006-04-11 Advancis Pharmaceutical Corp. Multiple-delayed released antibiotic product, use and formulation thereof
US6663891B2 (en) 2000-02-24 2003-12-16 Advancis Pharmaceutical Corp. Erythromyacin antibiotic product, use and formulation thereof
US6623757B2 (en) 2000-02-24 2003-09-23 Advancis Pharmaceutical Corp. Antibiotic composition
US6667057B2 (en) 2000-02-24 2003-12-23 Advancis Pharmaceutical Corp. Levofloxacin antibiotic product, use and formulation thereof
US7985420B2 (en) 2000-04-28 2011-07-26 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US6955821B2 (en) 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
US7838032B2 (en) 2000-04-28 2010-11-23 Reckitt Benckiser Inc. Sustained release of guaifenesin
US8012504B2 (en) 2000-04-28 2011-09-06 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
EP1330236A2 (fr) 2000-10-12 2003-07-30 Beecham Pharmaceuticals (Pte) Limited Nouvelle formulation
US6756057B2 (en) 2000-10-12 2004-06-29 Beecham Pharmaceuticals (Pte) Limited Amoxicillin and potassium clavulanate dosage form
US7074417B2 (en) 2000-10-13 2006-07-11 Advancis Pharmaceutical Corporation Multiple-delayed release anti-viral product, use and formulation thereof
US7157095B2 (en) 2000-10-13 2007-01-02 Advancis Pharmaceutical Corporation Multiple-delayed release antifungal product, use and formulation thereof
US6541014B2 (en) 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US7105174B2 (en) 2000-10-13 2006-09-12 Advancis Pharmaceutical Corporation Multiple-delayed release anti-neoplastic product, use and formulation thereof
US20020197314A1 (en) 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
AT413015B (de) * 2001-04-12 2005-10-15 Sandoz Ag Tablette enthaltend das k-salz der 3-(2-hydroxyethyliden)-7-oxo-4-oxa-1- azabicyclo(3.2.0)heptan-2 carbonsäure in hydrophobisierter form
GB0209265D0 (en) * 2002-04-23 2002-06-05 Novartis Ag Organic compounds
BR0318167A (pt) * 2003-03-04 2006-02-21 Nostrum Pharmaceuticals Inc formulação de liberação controlada contendo um material hidrofóbico como o agente de liberação controlada
WO2005016278A2 (fr) 2003-08-12 2005-02-24 Advancis Pharmaceuticals Corporation Antibiotique, utilisation et formulation associees
BRPI0417348A (pt) * 2003-12-04 2007-03-13 Pfizer Prod Inc processo de gelatinização por spray com utilização de uma extrusora para preparação de composições de droga cristalina multiparticulada contendo preferencialmente um poloxámero e um glicerìdeo
AU2004294813A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Spray-congeal process using an extruder for preparing multiparticulate azithromycin compositions containing preferably a poloxamer and a glyceride
US6984403B2 (en) 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
AR050615A1 (es) * 2004-08-27 2006-11-08 Novartis Ag Composiciones farmaceuticas para la administracion oral
US7776897B2 (en) 2004-09-16 2010-08-17 Astellas Pharma Inc. Triazole derivative or salt thereof
EP2590634B1 (fr) 2010-07-09 2016-03-09 BHV Pharma, Inc. Système d'administration à libération immédiate/retardée en combinaison pour des médicaments à courte demi-vie comprenant de la rémogliflozine
GB201506755D0 (en) 2015-04-21 2015-06-03 Reckitt Benckiser Llc Novel pharmaceutical formulation
GB201420311D0 (en) 2014-11-14 2014-12-31 Bio Images Drug Delivery Ltd Pharmaceutical processing
GB201420306D0 (en) 2014-11-14 2014-12-31 Bio Images Drug Delivery Ltd Compositions
EP3364955B1 (fr) 2015-10-09 2022-04-20 RB Health (US) LLC Formulation pharmaceutique
WO2021004912A1 (fr) 2019-07-05 2021-01-14 Glaxosmithkline Intellectual Property (No.2) Limited Streptomyces clavuligerus

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4132753A (en) * 1965-02-12 1979-01-02 American Cyanamid Company Process for preparing oral sustained release granules
JPS56140915A (en) * 1980-04-07 1981-11-04 Yamanouchi Pharmaceut Co Ltd Pharmaceutical preparation for solid drug
US5169645A (en) * 1989-10-31 1992-12-08 Duquesne University Of The Holy Ghost Directly compressible granules having improved flow properties

Also Published As

Publication number Publication date
EP0701436A4 (fr) 1997-05-21
ES2189803T3 (es) 2003-07-16
NZ268172A (en) 1997-12-19
AU684522B2 (en) 1997-12-18
WO1994027557A3 (fr) 1995-03-16
IL109770A0 (en) 1994-11-28
AP9400645A0 (en) 1994-07-31
EP0701436B1 (fr) 2003-01-15
EP0701436A1 (fr) 1996-03-20
ATE230981T1 (de) 2003-02-15
AU7096294A (en) 1994-12-20
JPH08510752A (ja) 1996-11-12
DE69432015D1 (de) 2003-02-20
DE69432015T2 (de) 2003-11-06
WO1994027557A2 (fr) 1994-12-08
CA2164003A1 (fr) 1994-12-08
CN1124452A (zh) 1996-06-12

Similar Documents

Publication Publication Date Title
MA23212A1 (fr) Procede
FI961430L (fi) Prosessi I
DE69430061D1 (de) Entsalzungsverfahren
DE69420020D1 (de) Bildherstellungsverfahren
FI961431L (fi) Prosessi II
DE69620107D1 (de) Kristallisationsverfahren
DE69520558D1 (de) Halogenierungsverfahren
FI932871L (fi) Stereoselektiv anjonglykosylationsprocess
DE69414324D1 (de) Elektrobeschichtungsverfahren
DE69433163D1 (de) Filmherstellungsverfahren
DE69318527D1 (de) Entwicklungsverfahren
DE69507032D1 (de) Chlorhydrin-verfahren
DE69402778D1 (de) Alkylierungsverfahren
DE69219741D1 (de) Hydrolisylierungsverfahren
MA24472A1 (fr) Procede
DE69304725D1 (de) Hydrobehandlungsverfahren
DE4493351T1 (de) Papierherstellungsverfahren
DE59403372D1 (de) Streckverfahren
DE69417308D1 (de) Decarboxylierungsverfahren
MA22366A1 (fr) Procede de desalcoolisation
MA22980A1 (fr) Procede.
MA22762A1 (fr) Procede.
DE69309870D1 (de) Drehverfahren
FI931051A7 (fi) Kuvausmenetelmä
DE69311334D1 (de) Alkylierungsverfahren